Gestational Diabetes Tied to 11-Fold Higher Risk of Diabetes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, June 28, 2023 -- Women with gestational diabetes mellitus (GDM) face a substantially higher risk of later diabetes, according to a study published online June 21 in Diabetes Care.
Katharine J. McCarthy, Ph.D., M.P.H., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues estimated racial and ethnic differences in the influence of GDM on diabetes risk and glycemic control. Analysis included a final birth cohort of 336,276 women (2009 to 2017).
The researchers found that the cumulative incidence for diabetes was 11.8 percent for women with GDM and 0.6 percent among women without GDM. Diabetes risk with GDM was more than 11-fold higher overall (adjusted hazard ratio, 11.5), with slight differences seen by race and ethnicity. Further, GDM was associated with a lower likelihood of glycemic control (adjusted hazard ratio, 0.85), with highest risk among Black women (adjusted hazard ratio, 0.77) and Hispanic women (adjusted hazard ratio, 0.84).
"Our findings highlight the importance of regular diabetes screening following a gestational diabetes, particularly in the first 12 months following delivery -- which was marked by the highest incidence of diabetes and least likelihood of glycemic control -- in order to facilitate early detection and appropriate diabetes management," McCarthy said in a statement. "In addition to care coordination between obstetric and primary care providers, provider education on the importance of obstetric history-taking is essential in facilitating diabetes awareness and early glycemic control."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.